INSU Cor Study: Insular – non Insular Stroke Underlying Cardiac failure
- Conditions
- I63I64I50Cerebral infarctionStroke, not specified as haemorrhage or infarctionHeart failure
- Registration Number
- DRKS00012454
- Lead Sponsor
- niversitätsklinikum WürzburgNeurologischen Klinik und Poliklinik
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 180
Ischemic stroke according to the WHO definition (Hatano 1976) or the corresponding lesion in cerebral imaging irrespective of the duration of the symptoms, maximum 3 days before inclusion with (cases) vs. without involvement (control) of the insular cortex
In screening by handheld or routine echocardiography free of systolic dysfunction
Written consent of the patient or written consent of the legal representative or relative is available
Sufficient German language skills
The exclusion criterion is the inclusion of the patient in an acute intervention / AMG study in order to monitor the natural course of cardiovascular diseases as well as comorbidities
Patients who were initially diagnosed with a stroke but who were subsequently diagnosed with a different diagnosis
Systolic dysfunction in screening
Lack of readiness / ability to perform follow-up appointments
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint is the development of new systolic dysfunction in ischemic cerebral infarction patients with involvement of the insular cortex within the first three months after index event.
- Secondary Outcome Measures
Name Time Method Identification of comorbidities (rehospitalisation rate, degree of independence, cognition, depression, anxiety) after 3 months, that are associated with development of a new systolic dysfunktion within the first three months after ischemic stroke<br>Cases and controls are compared by means of echocardiographic and clinical exams, blood based biomarkers, interviews about comorbidities, medication and risk factors after 1 week as well as 4 and 12 weeks.